Members of OCRF’s senior staff and Scientific Advisory Committee recently attended the Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer in Austin, TX. Now in its 43rd year, the Annual Meeting on Women’s Cancer continues to be the premier educational activity for women’s cancer care professionals.
Data Confirm PARP Inhibitor Slows Ovarian Cancer
Data presented at the SGO’s annual meeting last week suggest that patients with recurrent, platinum-sensitive ovarian cancer had a significant improvement in progression-free survival when they took olaparib, a PARP-inhibitor, as maintenance therapy. Click here for more.
Experimental Combination Treatment Promising for Resistant Ovarian Cancer
Data from a phase II clinical trial showed that patients with platinum-resistant ovarian cancer had a twofold increase in progression-free survival when treated with an experimental folate conjugate. Click here for more info.
Most Ovarian Cancer Patients Receive Suboptimal Treatment; Health Disparities Also Exist
A study presented at SGO showed less than half of all women with ovarian cancer receive optimal care. Furthermore, black women, uninsured women, and those on Medicaid or with annual incomes under $35,000 received poorer quality care and were less likely to survive for five years after diagnosis. Click here for more info.